■这项研究确定了Ki-67表达的临界值,并讨论了Ki-67与组织学分级之间的相互作用,进一步探讨Ki-67在激素受体阳性和人表皮生长因子受体2阴性(HR+/HER2-)乳腺癌中的预后作用。
■我们通过免疫组织化学(IHC)评估了2015年至2019年在宁夏医科大学总医院诊断的956例HR/HER2乳腺癌患者的Ki-67表达,无病生存期(DFS)定义为从术后到首次局部复发的时间,远处转移或疾病死亡。通过住院或门诊病历和电话进行随访。
■22.5%用作HR+/HER2-乳腺癌中Ki-67低/高表达的截止值。与14%的值相比,这是目前临床上常用的,两个值的一致性中等(Kappa=0.484,P<0.001)。Ki-67的表达随品级增加而增加。(中值:G1:10%;G2:20%;G3:40%。平均值:G1:13%;G2:23%;G3:39%,P<0.001)。生存分析基于所有患者,中位时间为51个月(24-89个月),63例随访中复发或转移,其中21例Ki-67低表达,42例高表达。Ki-67≥22.5%的患者早期复发和转移的风险高于Ki-67<22.5%的患者2.969。有4例局部复发,7例区域淋巴结转移,所有患者中有52例远处转移,常见的远处转移是骨,肝脏,和肺,罕见的转移是肾上腺,骨髓,和心包.
■在HR+/HER2-乳腺癌中,Ki-67>22.5%的患者预后较差,更容易出现早期复发和转移.
UNASSIGNED: This study determined the cut-off value of Ki-67 expression and discussed the interaction between Ki-67 and histological grade, further explored the prognostic role of Ki-67 in hormone receptor-positive and human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer;.
UNASSIGNED: We assessed the Ki-67 expression of 956 patients with HR+/HER2 breast cancer diagnosed in the General Hospital of Ningxia Medical University from 2015 to 2019 by immunohistochemistry (IHC), The disease-free survival (DFS) was defined as the time from postoperative to the first local recurrence, distant metastasis or death of the disease. The follow-up by means of inpatient or outpatient medical records and telephone.
UNASSIGNED: 22.5% was used as the cut-off for low/high Ki-67 expression in HR+/HER2- breast cancer. Compared with the value of 14%, which is commonly used in clinic at present, the consistency of the two values is moderate (Kappa = 0.484, P<0.001). The expression of Ki-67 was increased with the grade. (Median: G1:10%; G2:20%; G3:40%. Mean: G1:13%; G2:23%; G3:39%, P <0.001). Survival analysis was based on all patients for a median of 51 months (24-89 months), 63 cases had recurrence or metastasis during the follow-up, which 21 cases had low expression of Ki-67 and 42 cases had high expression. The patients with Ki-67 ≥ 22.5% had a 2.969 higher risk of early recurrence and metastasis than the patients with Ki-67 < 22.5%. There were 4 cases of local recurrence, 7 cases of regional lymph node metastasis, and 52 cases of distant metastasis in all patients, the common distant metastases were bone, liver, and lung, and rare metastases were adrenal gland, bone marrow, and pericardium.
UNASSIGNED: In HR+/HER2- breast cancer, patients with Ki-67 > 22.5% have a worse prognosis and are more likely to have early recurrence and metastasis.